Other invited drugmakers, including AstraZeneca, are still weighing whether to attend what's likely to be a high-profile hearing in front of the powerful Senate Finance committee.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,